Benzinga
09 Jul 2026, 17:37 UTC · 2h ago
Can ARS Pharma's New CEO Unlock Neffy's Potential?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Benzinga
09 Jul 2026, 17:37 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
William Blair lowered the fair value estimate for ARS Pharmaceuticals (SPRY) from $31 to $21 per share. — A significant reduction in analyst fair value estimates usually triggers immediate downward price pressure.
-0.80The peak market penetration estimate for Neffy was reduced from 40% to 25% due to a more cautious outlook. — Lowering long-term market share expectations directly reduces the projected terminal value of the company's primary product.
-0.70ARS Pharmaceuticals appointed Donn Casale, a veteran with commercial experience at Dynavax and Sanofi, as the new CEO. — Bringing in a leader with a proven track record of building market-leading franchises provides a catalyst for operational turnaround.
+0.40Continue reading
6 related stories
Top 1 mover · tap to explore
Projected second-quarter Neffy revenue was revised down to $26.4 million, trailing the consensus estimate of $28.6 million. — An expected miss relative to consensus estimates typically leads to short-term negative price volatility.
-0.30Which stocks this story touches
The company is facing a leadership change due to poor stock performance and a product launch that has not lived up to expectations, leading to lowered price targets and revenue estimates.
Mentioned only in the historical context of acquiring Dynavax Technologies.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Invezz
54m ago
